OTCM
OSRH
Market cap7mUSD
Oct 19, Last price
0.21USD
1D
-7.08%
1Q
-52.00%
IPO
-93.25%
Name
Bellevue Life Sciences Acquisition Corp
Chart & performance
P/E
—
P/S
2.54
EPS
—
Div yield, %
—
Shs. 5Y
-10.69%
Rev. 5Y
%
Revenues
3m
-17.69%
Net income
-18m
L+74.37%
CFO
-4m
L+97.81%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bellevue Life Sciences Acquisition Corp. currently does not engage in substantial operational activities. Its core mission is to orchestrate a business combination, which could manifest as a merger, share exchange, asset acquisition, stock purchase, recapitalization, or reorganization, with one or more enterprises or organizations within the healthcare domain. This firm, established in 2020, maintains its principal office in Bellevue, Washington, and operates as a subordinate entity of Bellevue Global Life Sciences Investors LLC.
Key people
Hyoun Hwang Kuk
President, Chief Executive Officer · since 2025
Gihyoun Bang
Chief Financial Officer · since 2025
Constance Hofer
Chief Scientific Officer · since 2025
Jun Chul Whang
Chief Legal Officer, Company Secretary, Director · since 2025
Alcide Barberis
Independent Director · since 2025
Independent Director · since 2025
Joong Myung Cho
Independent Director · since 2025
Hyuk Joo Jee
Independent Director · since 2025
Phil Geon Lee
Independent Director · since 2024
Jin Park
Independent Director · since 2023
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||